FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
We haven't written up this one. NPR Health has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.